Page 3 - Harbour Biomed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals

JPM24: Even after Seagen buyout, Pfizer oncology chief still eyes ADC deals
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesMerck keytrudaRoche kadcylaNona biosciencesDaiichi sankyo enhertuChris boshoffSuneet varmaFar eastHarbour biomedMedilink therapeuticsAstellas partnered padcevAstellas partnered xtandiDaiichi sankyo

Week In Review: Two Billion-Dollar Deals As 2023 Nears End - Hansoh-GSK; Nona-Pfizer

Week In Review: Two Billion-Dollar Deals As 2023 Nears End - Hansoh-GSK; Nona-Pfizer
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalComunidad autonoma de catalunaJiangsu hansoh pharmaBiocytogen pharmaNona biosciencesCstone pharmaAi foundation large language modelAgios pharmaceuticalsGreater chinaHansoh pharmaChina phasePhasei chinaHarbour biomedHarbour miceMedilink therapeutics

BioBlast w/e 15 Dec 23

Korea Biomed reported that LG Chem’s Xelenka®, biosimilar to AbbVie’s Humira® (adalimumab), has been approved by the Korean Ministry of Food and Drug…

South koreaLendava lendvaSamsung biologicsBiomed nona biosciencesNona biosciencesGenentech avastinSeagen astella padcevCelltrion vegzelmaGenentech actemraAbbvie humiraKorea ministry of foodIntas pharmaceuticalsKorean ministry of foodJapan national health insuranceApproval alertKorean ministry

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out

Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesShruti thakurViela bioDemyelinating polyneuropathyDemyelinating polyneuropathytherapiesPrnewswire delveinsightJanssen research developmentDelveinsight key companies to watchKey chronic inflammatory demyelinating polyneuropathy companiesCatalyst pharmaceuticals incBioasis technologies incDelveinsight business researchRa pharmaceuticals incIra pharmaceuticalsImmunovant sciences

Form 10-Q Cullinan Oncology, Inc For: Sep 30

Form 10-Q Cullinan Oncology, Inc For: Sep 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongMassachusetts institute of technologyUnited statesUnited kingdomKarl dane wittrupDeutsches krebsforschungszentrumJeffrey trigilioCullinan amberCullinan pearlNadim ahmedMonte carloCullinan florentineBiotechnology value trading fundExchange commissionParty transactionsGrowth company status